Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy - Peggy Sotiropoulou Ph.D. -...

Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy - Peggy Sotiropoulou Ph.D. -...

User Photo
Cancer-News

1 month
17 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Peggy Sotiropoulou, Ph.D. - Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Up Next Autoplay